Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/115633
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bahhaj, F.E. | - |
dc.contributor.author | Denis, I. | - |
dc.contributor.author | Pichavant, L. | - |
dc.contributor.author | Delatouche, R. | - |
dc.contributor.author | Collette, F. | - |
dc.contributor.author | Linot, C. | - |
dc.contributor.author | Pouliquen, D. | - |
dc.contributor.author | Grégoire, M. | - |
dc.contributor.author | Héroguez, V. | - |
dc.contributor.author | Blanquart, C. | - |
dc.contributor.author | Bertrand, P. | - |
dc.date.issued | 2016 | - |
dc.identifier.citation | Theranostics, 2016; 6(6):795-807 | - |
dc.identifier.issn | 1838-7640 | - |
dc.identifier.issn | 1838-7640 | - |
dc.identifier.uri | http://hdl.handle.net/2440/115633 | - |
dc.description.abstract | Fast clearance, metabolism and systemic toxicity are major limits for the clinical use of anti-cancer drugs. Histone deacetylase inhibitors (HDACi) present these defects despite displaying promising anti-tumor properties on tumor cells in vitro and in in vivo model of cancers. Specific delivery of anti-cancer drugs into the tumor should improve their clinical benefit by limiting systemic toxicity and by increasing the anti-tumor effect. In this work, we describe a simple and flexible polymeric nanoparticle platform highly targeting the tumor in vivo and triggering impressive tumor weight reduction when functionalized with HDACi. Our nanoparticles were produced by Ring-Opening Metathesis Polymerization of azido-polyethylene oxide-norbornene macromonomers and functionalized using click chemistry. Using an orthotopic model of peritoneal invasive cancer, a highly selective accumulation of the particles in the tumor was obtained. A combination of epigenetic drugs involving a pH-responsive histone deacetylase inhibitor (HDACi) polymer conjugated to these particles gave 80% reduction of tumor weight without toxicity whereas the free HDACi has no effect. Our work demonstrates that the use of a nanovector with theranostic properties leads to an optimized delivery of potent HDACi in tumor and then, to an improvement of their anti-tumor properties in vivo. | - |
dc.description.statementofresponsibility | Fatima el Bahhaj, Iza Denis, Loic Pichavant, Régis Delatouche, Floraine Collette, Camille Linot, Daniel Pouliquen, Marc Grégoire, Valérie Héroguez, Christophe Blanquart, Philippe Bertrand | - |
dc.language.iso | en | - |
dc.publisher | Ivyspring International | - |
dc.rights | © Ivyspring International Publisher. Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. See http://ivyspring.com/terms for terms and conditions. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions. | - |
dc.source.uri | http://dx.doi.org/10.7150/thno.13725 | - |
dc.subject | Polymeric nanoparticle; epigenetic; HDAC; cancer; theranostics; peritoneal; mesothelioma | - |
dc.title | Histone deacetylase inhibitors delivery using nanoparticles with intrinsic passive tumor targeting properties for tumor therapy | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.7150/thno.13725 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Denis, I. [0000-0002-2882-4306] | - |
Appears in Collections: | Aurora harvest 3 Medicine publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
hdl_115633.pdf | Published Version | 1.58 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.